Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome

By D. Teachey, R. Greiner, A. Seif, E. Attiyeh, J. Bleesing, J. Choi, C. Manno, E. Rappaport, D. Schwabe, C. Sheen and 4 more. 2009

175 citations recorded by the source corpus.

We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies. Four patients were treated for autoimmune cytopenias; all had a rapid complete or near complete response. Two patients were treated for autoimmune arthritis and colitis, demonstrating marked improvement. Three patients had complete resolution of lymphadenopathy and splenomegaly and all patients had a reduction in double negative T cells, a population hallmark of the disease. Based on these significant responses, we recommend that sirolimus be considered as second‐line therapy for patients with steroid‐refractory disease.

Subfields: Genetics, Immunology, Oncology

Citations in the corpus

• SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, neutral): “comparison to de novo design[4-11].”
• The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease (2014, unknown): “The timely diagnosis of monogenic IBD requires assessments of intestinal and extraintestinal disease phenotypes in conjunction with the histopathology and appropriate laboratory tests to exclude allergies or infections.(18,19) Classification of clinical, endoscopic, histological, and imaging finding”